Stem definition | Drug id | CAS RN |
---|---|---|
antineoplastics, nucleotoxic agents | 1819 | 50-07-7 |
None
Property | Value | Reference |
---|---|---|
S (Water solubility) | 0.50 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
fu (Fraction unbound in plasma) | 0.79 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 24, 1981 | FDA | ||
Dec. 23, 2022 | PMDA | Kyowa Kirin Co., Ltd. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 108.08 | 29.19 | 122 | 2018 | 674340 | 62812542 |
Pulmonary veno-occlusive disease | 105.56 | 29.19 | 20 | 2120 | 1101 | 63485781 |
Conjunctival filtering bleb leak | 97.52 | 29.19 | 11 | 2129 | 6 | 63486876 |
Haemolytic uraemic syndrome | 84.09 | 29.19 | 19 | 2121 | 2484 | 63484398 |
Iris transillumination defect | 69.59 | 29.19 | 10 | 2130 | 94 | 63486788 |
Scleral thinning | 66.68 | 29.19 | 8 | 2132 | 13 | 63486869 |
Leukopenia | 58.78 | 29.19 | 35 | 2105 | 77255 | 63409627 |
Scleromalacia | 58.11 | 29.19 | 7 | 2133 | 12 | 63486870 |
Mucosal inflammation | 57.11 | 29.19 | 29 | 2111 | 46899 | 63439983 |
Malignant neoplasm progression | 56.82 | 29.19 | 35 | 2105 | 82086 | 63404796 |
Neutropenia | 54.76 | 29.19 | 46 | 2094 | 174959 | 63311923 |
Thrombocytopenia | 52.01 | 29.19 | 42 | 2098 | 151115 | 63335767 |
Bladder perforation | 50.05 | 29.19 | 8 | 2132 | 160 | 63486722 |
Radiation skin injury | 47.57 | 29.19 | 10 | 2130 | 933 | 63485949 |
Eye infection toxoplasmal | 45.55 | 29.19 | 8 | 2132 | 287 | 63486595 |
Hypotony of eye | 43.37 | 29.19 | 7 | 2133 | 149 | 63486733 |
Necrotising scleritis | 43.33 | 29.19 | 7 | 2133 | 150 | 63486732 |
Tractional retinal detachment | 42.73 | 29.19 | 6 | 2134 | 47 | 63486835 |
Pancytopenia | 39.95 | 29.19 | 30 | 2110 | 96903 | 63389979 |
Extravasation | 38.39 | 29.19 | 10 | 2130 | 2362 | 63484520 |
Rhegmatogenous retinal detachment | 38.03 | 29.19 | 6 | 2134 | 110 | 63486772 |
Acute promyelocytic leukaemia | 36.41 | 29.19 | 8 | 2132 | 919 | 63485963 |
Disease progression | 31.75 | 29.19 | 29 | 2111 | 122729 | 63364153 |
Encapsulating peritoneal sclerosis | 31.41 | 29.19 | 6 | 2134 | 344 | 63486538 |
Conjunctival erosion | 30.45 | 29.19 | 5 | 2135 | 119 | 63486763 |
Metastases to liver | 29.87 | 29.19 | 15 | 2125 | 23624 | 63463258 |
Thrombotic thrombocytopenic purpura | 29.33 | 29.19 | 9 | 2131 | 3827 | 63483055 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 108.57 | 31.48 | 123 | 1800 | 419401 | 34535607 |
Conjunctival filtering bleb leak | 83.41 | 31.48 | 10 | 1913 | 6 | 34955002 |
Bladder perforation | 80.20 | 31.48 | 14 | 1909 | 292 | 34954716 |
Iris hypopigmentation | 64.04 | 31.48 | 9 | 1914 | 40 | 34954968 |
Scleral thinning | 57.34 | 31.48 | 7 | 1916 | 6 | 34955002 |
NPM1 gene mutation | 55.55 | 31.48 | 9 | 1914 | 117 | 34954891 |
Bronchiolitis obliterans syndrome | 51.13 | 31.48 | 9 | 1914 | 197 | 34954811 |
Chimerism | 49.64 | 31.48 | 9 | 1914 | 234 | 34954774 |
Post embolisation syndrome | 45.26 | 31.48 | 7 | 1916 | 66 | 34954942 |
Bladder necrosis | 44.05 | 31.48 | 5 | 1918 | 0 | 34955008 |
Scrotal ulcer | 37.70 | 31.48 | 8 | 1915 | 475 | 34954533 |
Gastric perforation | 37.28 | 31.48 | 11 | 1912 | 2509 | 34952499 |
Hypotony of eye | 35.30 | 31.48 | 6 | 1917 | 106 | 34954902 |
Eosinophilic cystitis | 34.46 | 31.48 | 5 | 1918 | 29 | 34954979 |
Blood immunoglobulin G decreased | 33.49 | 31.48 | 9 | 1914 | 1464 | 34953544 |
Dysuria | 33.47 | 31.48 | 20 | 1903 | 27132 | 34927876 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Conjunctival filtering bleb leak | 176.93 | 27.26 | 21 | 4084 | 12 | 79740271 |
Off label use | 173.02 | 27.26 | 221 | 3884 | 906994 | 78833289 |
Scleral thinning | 151.05 | 27.26 | 19 | 4086 | 29 | 79740254 |
Bladder perforation | 126.36 | 27.26 | 21 | 4084 | 346 | 79739937 |
Hypotony of eye | 111.87 | 27.26 | 18 | 4087 | 240 | 79740043 |
Scleromalacia | 103.66 | 27.26 | 14 | 4091 | 47 | 79740236 |
Pulmonary veno-occlusive disease | 100.42 | 27.26 | 22 | 4083 | 1626 | 79738657 |
Iris hypopigmentation | 77.44 | 27.26 | 11 | 4094 | 58 | 79740225 |
Mucosal inflammation | 74.22 | 27.26 | 47 | 4058 | 75533 | 79664750 |
Iris transillumination defect | 68.26 | 27.26 | 11 | 4094 | 148 | 79740135 |
NPM1 gene mutation | 62.37 | 27.26 | 10 | 4095 | 130 | 79740153 |
Encapsulating peritoneal sclerosis | 61.07 | 27.26 | 13 | 4092 | 838 | 79739445 |
Haemolytic uraemic syndrome | 60.83 | 27.26 | 18 | 4087 | 4431 | 79735852 |
Chimerism | 54.89 | 27.26 | 10 | 4095 | 286 | 79739997 |
Radiation skin injury | 54.32 | 27.26 | 13 | 4092 | 1421 | 79738862 |
Endophthalmitis | 54.30 | 27.26 | 18 | 4087 | 6410 | 79733873 |
Neutropenia | 53.91 | 27.26 | 70 | 4035 | 287640 | 79452643 |
Bronchiolitis obliterans syndrome | 53.54 | 27.26 | 10 | 4095 | 329 | 79739954 |
Conjunctival erosion | 52.30 | 27.26 | 9 | 4096 | 184 | 79740099 |
Post embolisation syndrome | 51.73 | 27.26 | 8 | 4097 | 81 | 79740202 |
Extravasation | 50.51 | 27.26 | 15 | 4090 | 3735 | 79736548 |
Eosinophilic cystitis | 50.04 | 27.26 | 8 | 4097 | 102 | 79740181 |
Leukopenia | 49.86 | 27.26 | 44 | 4061 | 116469 | 79623814 |
Gastric perforation | 49.42 | 27.26 | 15 | 4090 | 4022 | 79736261 |
Thrombocytopenia | 47.28 | 27.26 | 63 | 4042 | 265196 | 79475087 |
Bladder necrosis | 45.46 | 27.26 | 6 | 4099 | 16 | 79740267 |
Necrotising scleritis | 43.61 | 27.26 | 8 | 4097 | 238 | 79740045 |
Pupillary disorder | 42.48 | 27.26 | 9 | 4096 | 567 | 79739716 |
Scrotal ulcer | 39.15 | 27.26 | 8 | 4097 | 422 | 79739861 |
Blebitis | 38.88 | 27.26 | 5 | 4100 | 10 | 79740273 |
Acute promyelocytic leukaemia | 38.79 | 27.26 | 10 | 4095 | 1481 | 79738802 |
Visual acuity reduced | 38.40 | 27.26 | 22 | 4083 | 29447 | 79710836 |
Eye infection toxoplasmal | 37.16 | 27.26 | 8 | 4097 | 544 | 79739739 |
Pancytopenia | 36.86 | 27.26 | 44 | 4061 | 165701 | 79574582 |
Conjunctival bleb | 36.68 | 27.26 | 6 | 4099 | 89 | 79740194 |
Tractional retinal detachment | 36.62 | 27.26 | 6 | 4099 | 90 | 79740193 |
Choroidal detachment | 36.03 | 27.26 | 8 | 4097 | 628 | 79739655 |
Palmar-plantar erythrodysaesthesia syndrome | 36.01 | 27.26 | 22 | 4083 | 33112 | 79707171 |
Chemical cystitis | 35.50 | 27.26 | 4 | 4101 | 0 | 79740283 |
Acute myeloid leukaemia recurrent | 34.79 | 27.26 | 11 | 4094 | 3372 | 79736911 |
Second primary malignancy | 33.97 | 27.26 | 16 | 4089 | 14334 | 79725949 |
Rhegmatogenous retinal detachment | 32.34 | 27.26 | 6 | 4099 | 190 | 79740093 |
Hepatic artery stenosis | 32.22 | 27.26 | 6 | 4099 | 194 | 79740089 |
Dysuria | 31.81 | 27.26 | 24 | 4081 | 50927 | 79689356 |
Blood immunoglobulin G decreased | 30.62 | 27.26 | 10 | 4095 | 3399 | 79736884 |
Steroid diabetes | 30.34 | 27.26 | 10 | 4095 | 3496 | 79736787 |
Anterior chamber pigmentation | 30.21 | 27.26 | 4 | 4101 | 11 | 79740272 |
Disease progression | 30.09 | 27.26 | 42 | 4063 | 184320 | 79555963 |
Corneal oedema | 28.95 | 27.26 | 9 | 4096 | 2611 | 79737672 |
Hyphaema | 28.15 | 27.26 | 7 | 4098 | 897 | 79739386 |
None
Source | Code | Description |
---|---|---|
ATC | L01DC03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Other cytotoxic antibiotics |
FDA MoA | N0000000236 | Alkylating Activity |
FDA EPC | N0000175558 | Alkylating Drug |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
MeSH PA | D000477 | Alkylating Agents |
MeSH PA | D000903 | Antibiotics, Antineoplastic |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D003432 | Cross-Linking Reagents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D007202 | Indicators and Reagents |
MeSH PA | D009676 | Noxae |
MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Adenocarcinoma of pancreas | indication | 700423003 | DOID:4074 |
Metastatic Gastric Cancer | indication | ||
Adjunct to incisional glaucoma surgery | indication | ||
Non-small cell lung cancer | off-label use | 254637007 | DOID:3908 |
Malignant tumor of head and/or neck | off-label use | 255056009 | |
Malignant tumor of anus | off-label use | 363490009 | DOID:14110 |
Malignant tumor of urinary bladder | off-label use | 399326009 | DOID:11054 |
Prevention of Recurrent Bladder Carcinoma | off-label use | ||
Corneal Conjunctival Intraepithelial Neoplasm | off-label use | ||
Stomatitis | contraindication | 61170000 | DOID:9637 |
Acute infectious disease | contraindication | 63171007 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Hemolytic uremic syndrome | contraindication | 111407006 | DOID:12554 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Pulmonary Infiltrates | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.54 | acidic |
pKa2 | 10.39 | Basic |
pKa3 | 7.53 | Basic |
pKa4 | 4.95 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
0.2MG/VIAL | MITOSOL | MOBIUS THERAP | N022572 | Feb. 7, 2012 | RX | FOR SOLUTION | TOPICAL | 9539241 | Jan. 2, 2028 | MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY |
0.2MG/VIAL | MITOSOL | MOBIUS THERAP | N022572 | Feb. 7, 2012 | RX | FOR SOLUTION | TOPICAL | 9649428 | May 21, 2029 | MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
40MG/VIAL | JELMYTO | UROGEN PHARMA | N211728 | April 15, 2020 | RX | POWDER | PYELOCALYCEAL | April 15, 2023 | NEW PRODUCT |
40MG/VIAL | JELMYTO | UROGEN PHARMA | N211728 | April 15, 2020 | RX | POWDER | PYELOCALYCEAL | April 15, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC) |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Indoleamine 2,3-dioxygenase 1 | Enzyme | Ki | 4.60 | CHEMBL |
ID | Source |
---|---|
4018134 | VUID |
N0000146471 | NUI |
D00208 | KEGG_DRUG |
4018134 | VANDF |
C0002475 | UMLSCUI |
CHEBI:27504 | CHEBI |
CHEMBL105 | ChEMBL_ID |
D016685 | MESH_DESCRIPTOR_UI |
DB00305 | DRUGBANK_ID |
3043 | INN_ID |
50SG953SK6 | UNII |
5746 | PUBCHEM_CID |
204298 | RXNORM |
1274 | MMSL |
140168 | MMSL |
1973 | MMSL |
5122 | MMSL |
d00305 | MMSL |
002660 | NDDF |
387331000 | SNOMEDCT_US |
59240002 | SNOMEDCT_US |
7089 | IUPHAR_LIGAND_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9135 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 17 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9136 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 17 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9279 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 17 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9279 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 17 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9280 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 17 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9280 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 17 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-108 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-108 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-115 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-115 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-116 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-116 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-246 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-247 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-248 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-250 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 19 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-251 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 19 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-252 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 19 sections |
MITOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-564 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 15 sections |
MITOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-566 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 15 sections |
MITOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-568 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 15 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-518 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 16 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-519 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 16 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-520 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 16 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-995 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 16 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-996 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 16 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-997 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 16 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-389 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-390 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 18 sections |
Mitomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-391 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 40 mg | INTRAVENOUS | ANDA | 18 sections |